IL-2, IL-15 and IL-15 expanded TIL from primary solid cancer and metastatic lesions promotes the cultivation of a focused T-cell product directed against the patient’s autologous tumor cells and offers a viable treatment modality for patients with solid cancer. The gene discussed is IL15; the disease is neoplasm.